Infectology

Hypertension and nephrology

FEBRUARY 28, 2024

[Changes/new developments in pediatric nephrology I. – Vesicoureteral reflux (VUR)]

MÁTTYUS István

[In the case of vesicoureteral reflux (VUR), the abnormal backflow of urine from the bladder to the kidneys increases the risk of pyelonephritis and, in severe cases, causes kidney damage.]

HUN 2024;28(1)

Journal of Nursing Theory and Practice

DECEMBER 18, 2023

[Decreasing Fever now and then: The Past Living with us]

SIMON János

[To assess lay parents’ knowledge and attitudes towards fever; to find out to what extent they know and use fever control recommendations for their children; to assess whether the perceptions of parents who manage their children’s fever independently have changed. And to put this snapshot into context, it summaries how the perception of fever has changed through history to the present day.

The cross-sectional study was conducted between November 12, 2022 and December 24, 2022 through self-constructed online questionnaire among non-medical parents.

Most parents are not even aware of the basic concepts. If they do not have to manage their own fever, but their child’s, they will begin to reduce the fever much sooner. 58% of those surveyed also use physical methods (compresses, cooling baths) in addition to medication. Many misconceptions about fever persist. There is an opinion among parents that it is better to consult a physician than to manage fever on your own.

Disseminating knowledge about fever and tackling misconceptions would be vital to reduce the burden of overused emergency care.]

HUN 2023;36(6)

Hypertension and nephrology

DECEMBER 18, 2023

[Chronic kidney disease and obesity]

FREISINGER Lilla, NÉMETHY Orsolya, LELOVICS Zsuzsanna, SZLOVÁK Edina, DOLGOS Szilveszter

[Nowadays, the epidemic spread of obesity is mainly linked to changing environmental factors and is a serious public health problem. Obesity alone can be associated with increased mortality, but obesity is also an independent risk factor for several chronic diseases such as diabetes, hypertension and chronic kidney disease which have a major public health burden.]

HUN 2023;27(06)

Hypertension and nephrology

DECEMBER 18, 2023

[Complex therapeutic protection with SGLT2 inhibitors, focusing on the kidney]

LÉGRÁDY Péter

[In the EMPA-REG Outcome trial, it was already observed that cardiovascular (10.5% vs. 12.1%) and renal (1.7% vs. 3.1%) outcomes were better with empagliflozin treatment compared to placebo. The favorable effects of empagliflozin were consistent across the KDIGO risk categories. CVOT trials conducted with other SGLT2 inhibitors also concluded with promising renoprotective results.]

HUN 2023;27(06)

Hypertension and nephrology

OCTOBER 30, 2023

[High blood pressure and low testosterone levels both increase the risk of cardiovascular disease and alter the morphology and function of blood vessels]

JÓSVAI Attila, TÖRÖK Marianna, HETTHÉSSY Judit, SZÉKÁCS Béla, NÁDASY György, VÁRBÍRÓ Szabolcs

[Both hypertension and andropause alone increase the risk of cardiovascular disease. The incidence of both diseases increases with age. As a consequence they may often present concurrently in men. The damaging effects of the two noxae may add up - this may be observed in the remodeling processes of coronary resistance vessels. This mini-review summarizes the effects of hipertension, testosterone deficiency and the combined effects of these two noxae on the morphological, biomechanical and functional adaptation of coronary resistance vessels, as well as on cardiovascular diseases.]

HUN 2023;27(05)

Hypertension and nephrology

OCTOBER 30, 2023

[Chronic kidney disease and venous thromboembolic events]

VÁRADY Tímea, MÁCSAI Emília, SZLOVÁK Edina, DOLGOS Szilveszter

[Our aim is to analyse venous thromboembolic events regarding chronic kidney disease. Based upon epidemiologic data, both thromboembolic and haemorrhagic events are more frequent among patients with chronic kidney disease. Changes in levels of coagulant factors, thrombocyte and endothel disfunction, uremic toxins and dialysis related issues share role in pathogenesis. Guidelines lack of adequate information regarding this specific patient group. Therapeutic shift can be observed from vitamin K antagontists toward direct oral anticoagulants, not only in general population but also in CKD patients, with special interest in apixaban. Another therapeutic trend is change from unfractioned heparin to low molecular weigh heparins with anti Xa level monitoring among CKD population. Special attention is needed for thrombotic events related to eritropoietin therapy and hemodialysis access.]

HUN 2023;27(05)